Clinical trial · Observational
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer
Risk-guided Disease managEment Plan to prevEnt CAD in Patients Treated With Previous Cancer (REDEEM-CAD)
NCT05366153CI-TRIAL-00098442REDEEM-CADrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
REDEEM-CAD is a prospective multi-centre study of CAD risk evaluation and management in cancer survivors 40-70 years with chemotherapy or radiotherapy \>5 years ago.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Coronary Artery Disease | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Coronary CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Survivor Screening/Management Plan
- description
- In cancer survivors; 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
- interventionNames
- Diagnostic Test: Coronary CT
- label
- Non-cancer Screening/Management Plan
- description
- In matched non-cancer patients (from EDCAD trial); 1. A novel clinical and CT imaging-based screening algorithm to select those most likely to develop coronary artery disease, 2. A clinical review to ensure optimal risk factor control and cardiac protection.
- interventionNames
- Diagnostic Test: Coronary CT
Primary outcomes (1)
- measure
- Proportion of evaluated patients who should undergo CAD prevention
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: A history of cancer \>5 y ago associated with potential cardiotoxicity from chemotherapy and/or radiotherapy (chiefly survivors of breast cancer, Hodgkin's lymphoma and prostate cancer). Exclusion Criteria: * Unable to provide written informed consent to participate in this study * Known coronary artery disease at recruitment * History of previous coronary artery disease * Inability to acquire interpretable CT images * Contraindications/Intolerance to or already taking statin therapy * Oncologic (or other) life expectancy \<12 months or any other medical condition (including pregnancy) that results in the belief (deemed by the Chief Investigators) that it is not appropriate for the patient to participate in this trial
References
Publications (1)
- DERIVEDSoh CH, Smith J, Shrestha S, Nolan M, Wong J, Nerlekar N, Marwick TH. Screening for coronary artery disease among cancer survivors: rationale and design of the REDEEM-CAD study. Cardiooncology. 2025 Feb 4;11(1):10. doi: 10.1186/s40959-025-00308-7. PMID 39905553